NPVC

National Pharmaceutical Venture Capital (NPVC) is a specialized investment and development arm of the China National Pharmaceutical Group (Sinopharm), one of the largest healthcare conglomerates in Asia. The company focuses on identifying, investing in, and incubating high-growth life science and biotechnology enterprises both within China and internationally. NPVC leverages Sinopharm's extensive industrial resources, including manufacturing, distribution, and clinical trial networks, to accelerate the commercialization of innovative therapeutics and medical technologies. Its portfolio spans a wide range of modalities, including small molecules, biologics, and advanced cell therapies, with a primary focus on addressing unmet medical needs in oncology and chronic diseases.